Evidence map›Paper›PMID 40141095›Full record

ArticleInternational journal of molecular sciences2025

Transcriptional Expression of SLC2A3 and SDHA Predicts the Risk of Local Tumor Recurrence in Patients with Head and Neck Squamous Cell Carcinomas Treated Primarily with Radiotherapy or Chemoradiotherapy.

Mercedes Camacho, Silvia Bagué, Cristina Valero, Anna Holgado, Laura López-Vilaró, Ximena Terra, Francesc-Xavier Avilés-Jurado, Xavier León

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mercedes CamachoGenomics of Complex Diseases, Research Institute Hospital Sant Pau, IIB Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0001-5970-3294
Silvia BaguéPathology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
Cristina ValeroOtorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.ORCID 0000-0003-3397-2888
Anna HolgadoOtorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
Laura López-VilaróPathology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.ORCID 0000-0002-5428-8017
Ximena TerraMoBioFood Research Group, Biochemistry and Biotechnology Department, Universitat Rovira i Virgili, Campus Sescelades, 43007 Tarragona, Spain.ORCID 0000-0003-1043-5844
Francesc-Xavier Avilés-JuradoHead Neck tumors Unit, Hospital Clínic Barcelona, Universitat de Barcelona, IDIBAPS, 08036 Barcelona, Spain.ORCID 0000-0001-5560-8097
Xavier LeónOtorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.ORCID 0000-0001-6286-630X

Funding

Instituto de Salud Carlos III FIS PI18/0844 to F.AInstituto de Salud Carlos III PI24/01605 to X.L.
6 · The paper itself

Abstract

Reprogramming of metabolic pathways is crucial to guarantee the bioenergetic and biosynthetic demands of rapidly proliferating cancer cells and might be related to treatment resistance. We have previously demonstrated the deregulation of the succinate pathway in head and neck squamous cell carcinoma (HNSCC) and its potential as a diagnostic and prognostic marker. Now we aim to identify biomarkers of resistance to radiotherapy (RT) by analyzing the expression of genes related to the succinate pathway and nutrient flux across the cell membrane. We determined the transcriptional expression of succinate receptor 1 (SUCNR1), succinate dehydrogenase A (SDHA), and the solute carrier (SLC) superfamily transporters responsible for the influx or efflux of a wide variety of nutrients (SLC2A3 and SLC16A3) in tumoral tissue from 120 HNSCC patients treated with RT or chemoradiotherapy (CRT). Our results indicated that the transcriptional expression of the glucose transporter SLC2A3 together with SDHA had the best predictive capacity for local response after treatment with RT or CRT. High SLC2A3 and SDHA expression predicted poor outcomes after RT or CRT, with these patients having a 4.2 times higher risk of local recurrence compared to the rest of the patients. These results might indicate that tumors that shifted toward a higher glucose influx and a higher oxidation of succinate via mitochondrial complex II present an ideal environment for radioresistance development. Patients with a high transcriptional expression of both SLC2A3 and SDHA had a significantly higher risk of local recurrence after treatment with RT or CRT.

Indexed as

Carcinoma, Squamous CellGlucose Transporter Type 3Head and Neck NeoplasmsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckAdultAgedBiomarkers, TumorChemoradiotherapyFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorGlucose Transporter Type 3SLC2A3 protein, humanbiomarkerGLUT3head and neck squamous cell carcinomaSDHASLC16ASLC2A3SUCNR1Warburg effect

Identifiers

PMID40141095
PMCPMC11942407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.